Politician trade (House)

Biogen (BIIB)Rep. Maria Elvira Salazar (FL27) disclosed a sale $15K–$50K

Rep. Maria Elvira Salazar (FL27) disclosed a sale of Biogen in the $15K–$50K range.

$15,001–$50,000
Reported range · official band, not an exact amount
35 days
Disclosure lag
Traded
Jun 2, 2026
Disclosed
Jul 7, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Mar 27, 2026CongressDisclosed purchase of BIIB — reported range $1,001 - $15,000
  2. Apr 6, 2026Company filing · Form 8-K · ResultsReported its results
  3. Apr 29, 2026Company filing · Form 8-K · ResultsReported its results
  4. Apr 29, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
  5. May 6, 20265% stakeFMR LLC reported a passive stake (13G) of 8.7%
  6. May 11, 2026Congress · 1 personMembers of Congress: 2 purchases
  7. May 12, 2026CongressDisclosed purchase of BIIB — reported range $1,001 - $15,000
  8. May 14, 2026Company filing · Form 8-K · Material agreement, Acquisition or saleCompleted buying or selling a business or assets, and signed an important agreement (and 2 more items)“Pursuant to the Merger Agreement, on April 14, 2026, Purchaser commenced a tender offer (the “Offer”) to acquire any and all of the issued and outstanding Shares, in exchange for (i) $41.00 per Share, net to the seller in cash, without interest and subject to reduction for any applicable tax withholding (the “Cash Amount”), plus (ii) one contractual, non-transferable contingent value right per Share (each, a “CVR”)…”
  9. Jun 2, 2026 · this disclosureCongressDisclosed sale of BIIB — reported range $15,001 - $50,000

What came next

  1. Jun 5, 20265% stakeFMR LLC reported a passive stake (13G) of 11.3%
  2. Jun 5, 2026CongressDisclosed purchase of BIIB — reported range $1,001 - $15,000
  3. Jul 1, 2026Company filing · Form 8-K · ResultsReported its results
  4. Jul 23, 2026Government · Federal Register noticeAdvisory Committee; Peripheral and Central Nervous System Drugs Advisory Committee; Termination and Reestablishment
  5. Jul 29, 2026Company filing · Form 8-K · ResultsReported its results
  6. Aug 3, 2026InsiderDirector sold ~$121K of BIIB shares in the open market
  7. Aug 4, 2026InsiderDirector sold ~$119K of BIIB shares in the open market
  8. Aug 6, 20265% stakeFMR LLC reported a passive stake (13G) of 12.4%
  9. Aug 18, 2026CongressDisclosed sale of BIIB — reported range $1,001 - $15,000
  10. Sep 17, 2026Government · Federal Register noticeGranting of Requests for Early Termination of the Waiting Period Under the Premerger Notification Rules
View the official recordHouse Clerk periodic transaction report

How to read House Clerk periodic transaction report

The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.

Full guide: What is the STOCK Act?

What else is on file for Biogen

For Biogen, OQRO holds 2 insider filings (SEC Form 4 or Form 144), 3 Congress trade reports and 11 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its BIIB page.

Other recent filings by Rep. Maria Elvira Salazar (FL27)

The full history of Rep. Maria Elvira Salazar (FL27) is on the profile page.

How this filing works

Other disclosures at Biogen

Everything OQRO holds on this company is on its BIIB page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data